YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided unaudited earnings guidance for the year ended December 31, 2022. For the period, the Group is expected to record net profit attributable to the parent company of approximately RMB 68 million as compared to the net loss attributable to the parent company of approximately RMB 588 million for the year ended 31 December 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.16 HKD | +6.65% | +0.77% | +38.67% |
May. 08 | Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma | MT |
Apr. 09 | Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.67% | 1.48B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 1558 Stock
- News YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
- YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Unaudited Earnings Guidance for the Year Ended 31 December 2022